Collection of blood and tissue samples from patients with suspected or confirmed cancer
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Diseases
This study is collecting blood and tissue samples from patients with suspected or confirmed cancer to help researchers learn more about how these cancers develop and find new treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5950 (estimated) |
| Ages | 2 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00026884 on ClinicalTrials.gov |
What this trial studies
This observational study involves collecting blood and tissue samples from patients who have been diagnosed with or are suspected of having malignant diseases, particularly those affecting the genitourinary system. The samples will be stored in a tissue bank at the Urologic Oncology Branch of the National Cancer Institute (NCI) for future research. The study aims to investigate the genetic and molecular basis of these cancers to better understand their development and to identify potential therapeutic targets. By analyzing the differences between normal and tumor tissues, researchers hope to uncover critical insights into cancer pathways and treatment responses.
Who should consider this trial
Good fit: Ideal candidates include adults and minors with biopsy-proven malignant disease or those suspected of having such conditions, as well as family members of affected individuals.
Not a fit: Patients with co-morbidities that prevent surgical intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients with genitourinary cancers.
How similar studies have performed: Other studies have shown success in understanding cancer genetics and developing targeted therapies, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Individuals with biopsy-proven malignant disease * Individuals suspected of having a malignant disease * Individuals who have or are suspected of having an inherited genitourinary malignant disorder * Participants must be \>= 2 years of age * A relative (related by blood) of an individual with a confirmed or suspected diagnosis of a malignant disease or an inherited genitourinary malignant disorder. * All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. EXCLUSION CRITERIA: -Individuals whose co-morbidities preclude surgical intervention.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: W. Marston Linehan, M.D. — National Cancer Institute (NCI)
- Study coordinator: Deborah A Nielsen, R.N.
- Email: deborah.nielsen@nih.gov
- Phone: (240) 760-6247
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.